Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer

Background Epidermal growth factor receptor (EGFR) inhibitors prevent cell growth and have shown benefit in the treatment of metastatic colorectal cancer, whether used as single agents or in combination with chemotherapy. Clear benefit has been shown in trials of EGFR monoclonal antibodies (EGFR MAb...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cochrane database of systematic reviews 2017-06, Vol.2017 (7), p.CD007047
Hauptverfasser:	Chan, David Lok Hang, Segelov, Eva, Wong, Rachel SH, Smith, Annabel, Herbertson, Rebecca A, Li, Bob T, Tebbutt, Niall, Price, Timothy, Pavlakis, Nick
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal Antibodies, Monoclonal - therapeutic use Antineoplastic Agents Antineoplastic Agents - therapeutic use Bevacizumab Bevacizumab - therapeutic use Cancer Cancer: colorectal Colorectal Colorectal Neoplasms Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Diarrhea Diarrhea - chemically induced Diarrhea - epidemiology Disease-Free Survival ErbB Receptors ErbB Receptors - antagonists & inhibitors Exanthema Exanthema - chemically induced Exanthema - epidemiology Gastroenterology & hepatology Humans Medical & adjuvant therapy Medical therapy Medicine General & Introductory Medical Sciences Neoplastic diseases of the colon Neoplastic diseases of the rectum and anus Neutropenia Neutropenia - chemically induced Neutropenia - epidemiology Protein Kinase Inhibitors Protein Kinase Inhibitors - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Protein‐Tyrosine Kinases Proto-Oncogene Proteins p21(ras) - genetics Proto‐Oncogene Proteins p21(ras) Quality of Life Randomized Controlled Trials as Topic Treatment
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!